These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19933783)

  • 1. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
    Cantaert T; van Baarsen LG; Wijbrandts CA; Thurlings RM; van de Sande MG; Bos C; van der Pouw Kraan TC; Verweij CL; Tak PP; Baeten DL
    Rheumatology (Oxford); 2010 Jan; 49(1):156-66. PubMed ID: 19933783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
    Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
    Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
    Kolarz B; Majdan M; Dryglewska M; Darmochwal-Kolarz D
    Rheumatol Int; 2011 Nov; 31(11):1439-43. PubMed ID: 20473501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity and anti-TNF-alpha agents.
    Atzeni F; Turiel M; Capsoni F; Doria A; Meroni P; Sarzi-Puttini P
    Ann N Y Acad Sci; 2005 Jun; 1051():559-69. PubMed ID: 16126996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
    Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum and synovial fluid TNF-like ligand 1A (TL1A) is associated with autoantibody production in patients with rheumatoid arthritis.
    Sun X; Zhao J; Liu R; Jia R; Sun L; Li X; Li Z
    Scand J Rheumatol; 2013; 42(2):97-101. PubMed ID: 23311967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies.
    Laurent L; Anquetil F; Clavel C; Ndongo-Thiam N; Offer G; Miossec P; Pasquali JL; Sebbag M; Serre G
    Ann Rheum Dis; 2015 Jul; 74(7):1425-31. PubMed ID: 24618262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B; Stadlmaier E; Mulabecirovic A; Brezinschek R; Tilz G; Demel U; Mueller T; Brickmann K; Graninger WB; Brezinschek HP
    Ann Rheum Dis; 2005 Aug; 64(8):1224-6. PubMed ID: 16014683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis.
    Kastbom A; Roos Ljungberg K; Ziegelasch M; Wetterö J; Skogh T; Martinsson K
    Clin Exp Immunol; 2018 Dec; 194(3):391-399. PubMed ID: 30136282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in anti-citrullinated protein antibody titers following treatment with infliximab for rheumatoid arthritis.
    Vaz JL; Abreu MM; Levy RA
    Isr Med Assoc J; 2014 Jan; 16(1):17-9. PubMed ID: 24575499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.